| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44038890 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44045050 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038860 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038846 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44045033 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038859 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44045049 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44038858 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44045046 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
| TVIS44045059 | HTLV-1 | ENSG00000228716.7 | protein_coding | DHFR | No | No | 1719 | B4DM58 P00374 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | DHFR |
|---|---|
| DrugBank ID | DB01157 |
| Drug Name | Trimetrexate |
| Target ID | BE0000330 |
| UniProt ID | P00374 |
| Regulation Type | inhibitor |
| PubMed IDs | 10386066; 11448221; 11752096; 12416030; 12649191; 10091649; 21234348 |
| Citations | Bertino JR, Zhao SC, Mineishi S, Ercikan-Abali EA, Banerjee D: Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate. Prog Exp Tumor Res. 1999;36:82-94.@@Graffner-Nordberg M, Kolmodin K, Aqvist J, Queener SF, Hallberg A: Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. J Med Chem. 2001 Jul 19;44(15):2391-402.@@Warlick CA, Diers MD, Wagner JE, McIvor RS: In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model. J Pharmacol Exp Ther. 2002 Jan;300(1):50-6.@@Zhu WY, Bunni M, Priest DG, DiCapua JL, Dressler JM, Chen Z, Melera PW: Severe folate restriction results in depletion of and alteration in the composition of the intracellular folate pool, moderate sensitization to methotrexate and trimetrexate, upregulation of endogenous DHFR activity, and overexpression of metallothionein II and folate receptor alpha that, upon folate repletion, confer drug resistance to CHL cells. J Exp Ther Oncol. 2002 Sep-Oct;2(5):264-77.@@Sweeney CL, Frandsen JL, Verfaillie CM, McIvor RS: Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase. Cancer Res. 2003 Mar 15;63(6):1304-10.@@Polshakov VI, Birdsall B, Frenkiel TA, Gargaro AR, Feeney J: Structure and dynamics in solution of the complex of Lactobacillus casei dihydrofolate reductase with the new lipophilic antifolate drug trimetrexate. Protein Sci. 1999 Mar;8(3):467-81.@@Sowers R, Wenzel BD, Richardson C, Meyers PA, Healey JH, Levy AS, Gorlick R: Impairment of methotrexate transport is common in osteosarcoma tumor samples. Sarcoma. 2011;2011:834170. doi: 10.1155/2011/834170. Epub 2010 Dec 22. |
| Groups | Approved; Investigational |
| Direct Classification | Quinazolinamines |
| SMILES | COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC |
| Pathways | |
| PharmGKB | PA451790 |
| ChEMBL | CHEMBL119 |
